BioCentury
ARTICLE | Clinical News

MoxDuo IR: Phase II/III data

August 31, 2009 7:00 AM UTC

QRxPharma Ltd. (ASX:QRX), Brisbane, Australia Product: MoxDuo IR ( Q8003IR) Business: Neurology Molecular target: NA Description: Immediate-release combination of oxycodone and morphine Indication: T...